Skip To Main Content University of Washington Department of Rehabilitation Medicine
  Department of Rehabilitation Medicine 
  maximizing potential across the lifespan

Title:

Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial

Author(s):

Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, Adams J, Stover T, Sangeorzan A, Sloan A, Howieson D, Wild K, Haselkorn J, Bourdette D

Year:

2012

Publication Info:

Neurology, 79(12):1278-1284

Abstract:

OBJECTIVE: To determine whether Ginkgo biloba extract (ginkgo) improves cognitive function in persons with multiple sclerosis (MS).
METHODS: Persons with MS from the Seattle and Portland VA clinics and adjacent communities who scored 1 SD or more below the mean on one of 4 neuropsychological tests (Stroop Test, California Verbal Learning Test II [CVLT-II], Controlled Oral Word Association Test [COWAT], and Paced Auditory Serial Addition Task [PASAT]) were randomly assigned to receive either one 120-mg tablet of ginkgo (EGb-761; Willmar Schwabe GmbH & Co, Germany) or one placebo tablet twice a day for 12 weeks. As the primary outcome, we compared the performance of the 2 groups on the 4 tests at exit after adjusting for baseline performance.
RESULTS: Fifty-nine subjects received placebo and 61 received ginkgo; 1 participant receiving placebo and 3 receiving ginkgo were lost to follow-up. Two serious adverse events (AEs) (myocardial infarction and severe depression) believed to be unrelated to the treatment occurred in the ginkgo group; otherwise, there were no significant differences in AEs. The differences (ginkgo - placebo) at exit in the z scores for the cognitive tests were as follows: PASAT -0.2 (95% confidence interval [CI] -0.5 to 0.1); Stroop Test -0.5 (95% CI -0.9 to -0.1); COWAT 0.0 (95% CI -0.2 to 0.3); and CVLT-II 0.0 (95% CI -0.3 to 0.3); none was statistically significant.
CONCLUSIONS: Treatment with ginkgo 120 mg twice a day did not improve cognitive performance in persons with MS. Classification of evidence: This study provides Class I evidence that treatment with ginkgo 120 mg twice a day for 12 weeks does not improve cognitive performance in people with MS.

Link to Article:

http://www.ncbi.nlm.nih.gov/pubmed/22955125

Featured Research Articles

Multiple Sclerosis

View the latest research articles on Multiple Sclerosis written by faculty from the Department of Rehabilitation Medicine.

Volunteer to Participate in our Research Studies

The Department of Rehabilitation Medicine is looking for volunteers to participate in research studies on Multiple Sclerosis & Pain Management, and Traumatic Brain Injury.

Level A conformance icon, 
          W3C-WAI Web Content Accessibility Guidelines 1.0
Copyright © 2000-2017 University of Washington